← Back to Search

Alkylating agents

Zalutumumab 4 mg/kg for Squamous Cell Cancer

Phase 1 & 2
Waitlist Available
Led By Vincent Gregoire, MD professor
Research Sponsored by Genmab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer

Eligible Conditions
  • Head and Neck Cancers
  • Squamous Cell Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Secondary study objectives
Best Overall Tumor Response
Overall Response
Time to Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Zalutumumab 8 mg/kgExperimental Treatment3 Interventions
Zalutumumab 8 weekly infusions
Group II: Zalutumumab 4 mg/kgExperimental Treatment3 Interventions
Zalutumumab 8 weekly infusions
Group III: Zalutumumab 16 mg/kgExperimental Treatment3 Interventions
Zalutumumab 8 weekly infusions
Group IV: Zalutumumab 12 mg/kgExperimental Treatment3 Interventions
Zalutumumab 8 weekly infusions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zalutumumab
Not yet FDA approved
Cisplatin
FDA approved
Radiotherapy
2017
Completed Phase 3
~2610

Find a Location

Who is running the clinical trial?

GenmabLead Sponsor
70 Previous Clinical Trials
14,677 Total Patients Enrolled
Vincent Gregoire, MD professorPrincipal InvestigatorSt-Luc University Hospital, Brussels, Belgium
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top